AbbVie's Rinvoq Bolsters Its Potential In Atopic Dermatitis

JAK1 Inhibitor ‘Clears’ Second Of Three Phase III AD Trials

 
• By Sten Stovall
Steps
Late Stage Measure Up 2 study was second of three assessing Rinvoq in AD • Source: Shutterstock

More from Business

More from Scrip